vTv Therapeutics to Participate in Upcoming May Investor Conferences
Rhea-AI Summary
vTv Therapeutics (Nasdaq: VTVT) said management will attend two investor conferences in May 2026: H.C. Wainwright BioConnect in New York on May 19, 2026 and Alliance Global Partners Healthcare Company Showcase (virtual) on May 20, 2026.
Live fireside chat webcasts and replays will be available on the company website's Media & Events section.
Positive
- None.
Negative
- None.
News Market Reaction – VTVT
In the May 7 session, VTVT declined 2.02%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Inducement option grant | Neutral | +0.6% | Granted 4,000 stock options to a non-executive employee under inducement plan. |
| Mar 16 | Conference participation | Neutral | +7.4% | Announced fireside chat and 1x1 meetings at 38th Annual ROTH Conference. |
| Mar 10 | Earnings and update | Neutral | +0.2% | Reported 2025 results, cash of $88.9M, and CATT1 Phase 3 enrollment timing. |
| Feb 13 | Conference participation | Neutral | -7.2% | Outlined participation in Oppenheimer and TD Cowen healthcare conferences. |
| Feb 02 | License amendment | Positive | +8.2% | Expanded Newsoara license for HPP737 with $20M upfront and milestone structure. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Conference participation headlines have produced mixed reactions, while partnership and licensing news has coincided with stronger positive moves.
Over the past few months, vTv issued a mix of corporate and clinical updates. A February 2026 amendment granting Newsoara an exclusive worldwide license to HPP737 coincided with an 8.19% gain, while earlier February conference-participation news saw shares fall 7.18%. March 2026 earnings and corporate updates around cash levels and Phase 3 CATT1 enrollment prompted only modest positive reactions. Routine items like inducement option grants and other conference announcements generated relatively small price moves, framing today’s May investor-conference participation as a continuation of ongoing investor outreach rather than a new fundamental catalyst.
Key Terms
type 1 diabetes medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in May:
H.C. Wainwright 4th Annual BioConnect Investor Conference
Format: Fireside Chat & one-on-one investor meetings
Date: Tuesday, May 19, 2026
Time: 12:30 PM ET
Location: New York, NY
Webcast Link
Alliance Global Partners Healthcare Company Showcase
Format: Fireside Chat
Date: Wednesday, May 20, 2026
Time: 4:20 PM ET
Location: Virtual Event
Event Webcast Link
Live webcasts of the fireside chats will be available on the Media & Events section of the Company’s website at vtvtherapeutics.com. Replays of the webcasts will be available following the event.
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a U.S. Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased glucokinase activity independently of insulin. These findings support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
